Research suggests that gender-related differences in lung cancer survival are largely determined by known prognostic factors, suggesting an opportunity to explore gender differences in treatment preference, choice and accessibility.
HBM1020 is the world's first anti-B7H7 monoclonal antibody to be formally approved for clinical phase.
